Synergistic PD‐1/LAG‐3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy

Authors

Shiwei Duan (ORCID: https://orcid.org/0000-0001-7682-2877)
Hening Xu

Institutions

Communication University of Zhejiang (CN)
Hangzhou City University

Publication Details

Journal: MedComm
Published: 2025-05-20
DOI: https://doi.org/10.1002/mco2.70216
Primary Topic: Cancer Immunotherapy and Biomarkers
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Synergistic PD‐1/LAG‐3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy

Shiwei Duan, Hening Xu

May 20, 2025

MedComm

Cancer Immunotherapy and Biomarkers

article

Synergistic PD‐1/LAG‐3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy

Shiwei Duan, Hening Xu

May 20, 2025article en

Abstract

No abstract available for this paper.

MedCommVol. 6(6)

Communication University of Zhejiang (CN), Hangzhou City University

Openalex Percentile: Top 83%

Cancer Immunotherapy and Biomarkers

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Synergistic PD‐1/LAG‐3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy — Shiwei Duan, Hening Xu · MedComm (2025) | TGRS Research Map | TGRS